Cell Marque Disease of the Month – Lymphoma

Last updated: 02nd February, 2022

Products are for professional/laboratory use only.

LEF-1 and SOX-11 (MRQ-58) and – top IHC performers for your Lymphoma panel.

We are pleased to be launching the next edition of Cell Marque disease of the month. This is a continuation of a series of disease overviews where we will present commonly diagnosed disease groups and the relevant Cell Marque immunohistochemistry antibodies to assist in the disease diagnosis.
In this second edition, we will feature suitable Cell Marque IHC markers, LEF1 (EP310) and SOX 11 (MRQ-58), for use in the diagnosis of chronic lymphocytic leukemia (CLL).

Chronic lymphocytic leukemia/small lymphocytic lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are small B-cell neoplasms that make up almost 1% of all diagnosed cancers.  Small B-cell lymphoma subtypes are morphologically similar and can be distinguished from each other by immunohistochemistry.
The most common immunophenotype for CLL/SLL is CD20+, cyclin D1-, SOX-11-, CD23+, CD5+ and CD10-, which can be present in variable percentages.
For CLL/SLL CD23 is the standard diagnostic biomarker however 10-15% of CLL/SLL will be CD23-negative. Because of this phenomenon, other differential diagnostic markers exhibiting sensitivity and specificity for CLL/SLL are desirable.

Markers for CLL/SLL

Lymphoid-enhancer-binding factor-1 – LEF1
Lymphoid-enhancer-binding factor-1 (LEF1) is a nuclear marker that is expressed in up to 100% of CLL/SLL. A study from the Institute of Pathology, University Hospital Basel, Basel, Switzerland cited LEF1 as having a 92% specificity and 70% sensitivity for CLL/SLL lesions1.  LEF1 differentiates CLL/SLL from mantle cell lymphoma, follicular lymphoma and marginal-zone lymphoma and may detect CD23-negative CLL/SLL lesions.


The Cell Marque rabbit monoclonal SOX-11 is a nuclear marker that is expressed in mantle cell lymphomas in similar fashion to Cyclin D1. SOX-11 is able to detect up to 10% of mantle cell lymphomas that are Cyclin D1 negative and is therefore a valuable diagnostic tool in distinguishing mantle cell lymphoma from CLL/SLL, follicular lymphoma, and marginal zone lymphoma.

Cell Marque IHC antibodies
Abacus dx is able to offer Cell Marque LEF1 (EP310) and SOX 11 (MRQ-58) in concentrated and ready-to-use formats for IVD use.
Benefits of concentrated formats:

  • More efficient use of antibodies
  • Cost effective

Reduced storage requirements

Product Codes and Descriptions




View the NordiQC reports to review Cell Marque antibody performance

Download Assessment >

Contact us for a quote or sample

Contact Us Now >

View Cell Marque latest IHC Guide

Download Now >


1. https://www.ncbi.nlm.nih.gov/pubmed/25713417

Request a Quote

Request Quote

Go BackGo Back